Key result
Treatment with a GnRH agonist successfully managed superior vena cava syndrome in a patient presenting with this rare complication of metastatic prostate adenocarcinoma.
Case Report (n=1)
SVC syndrome can rarely present as a complication of metastatic prostate cancer, emphasizing the importance of pathological confirmation before treatment.
Prostate adenocarcinoma can cause SVC syndrome; extends known etiologies but case report leaves open any practice change.
Superior vena cava (SVC) syndrome is an uncommon complication of malignant disease caused by the obstruction of venous blood flow in the SVC. When present, a diagnosis of lung cancer or lymphoma will be made in approximately 95% of cases. Although other malignant diseases are occasionally associated with SVC, its occurrence in patients with prostate cancer is rare. We present a case of a patient presenting with SVC obstruction who was subsequently diagnosed with prostate adenocarcinoma. The patient has been successfully treated with GnRH agonist. This case reflects the importance of a full clinical assessment and pathological confirmation of suspected tumour prior to treatment.
No takes yet. Share an insight, caveat, or question.
Yun et al. (2012) conducted a case report in Superior vena cava syndrome and metastatic prostate cancer (n=1). GnRH agonist was evaluated on Successful treatment of SVC syndrome. Treatment with a GnRH agonist successfully managed superior vena cava syndrome in a patient presenting with this rare complication of metastatic prostate adenocarcinoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: